Characteristics | Patients (n = 67) |
---|---|
Age, years | 37.0 ± 11.8 |
Male gender, % | 47.8 |
Clinical manifestation of Fabry disease, % | |
Skin findings | 17.9 |
Hearing loss | 20.9 |
Cornea verticillata | 50.7 |
Heart involvement | 43.2 |
Stroke | 16.4 |
Acroparesthesia | 67.1 |
Kidney involvement | 65.7 |
Lyso-Gb3, ng/ml | 10.7 ± 11.5 |
Median (min–max) | 6.3 (0.5–42.2) |
Enzyme replacement therapy, % | 86.6 |
Agalsidase alfa | 75.9 |
Agalsidase beta | 24.1 |
ERT duration, years | 4.6 ± 3.7 |